https://doi.org/10.48047/AFJBS.6.2.2024.4173-4180

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Effects of Resveratrol on Peripheral Neuropathy Status in metabolic syndrome

Enas Ibrahim Eldosoky Shaaban, Azza Abd-Alrahman Youssef Megahed, Dalia Ibrahim Abd-Alaleem, Maha Abd Elhamid Fathy

Medical Physiology Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Enas Ibrahim Eldosoky Shaaban

Email: lamisenas@gmail.com, EIShaaban@medicine.zu.edu.eg

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 1 August 2024

Accepted: 15 August 2024

Published: 17 August 2024

doi:10.48047/AFJBS.6.2.2024.4173-4180

Abstract: Resveratrol, a natural polyphenol with antioxidative and anti-inflammatory properties, has garnered attention for its potential therapeutic effects on metabolic syndrome (MetS) and its associated complications. Among these complications, peripheral neuropathy is a debilitating condition characterized by nerve damage, often linked to chronic inflammation, oxidative stress, and metabolic dysregulation. Emerging evidence suggests that resveratrol may exert neuroprotective effects by modulating molecular pathways associated with metabolic health. This review focuses on the relationship between resveratrol, Klotho—a protein implicated in longevity and metabolic regulation—and peripheral neuropathy status in individuals with MetS. Klotho acts as a protective factor against oxidative stress and inflammation, processes central to both MetS and neuropathy. Resveratrol has been shown to upregulate Klotho expression in experimental models, suggesting a mechanism by which it may mitigate neuropathic symptoms and improve metabolic parameters. The article explores the mechanistic pathways linking resveratrol to Klotho expression, including the activation of sirtuins, modulation of insulin signaling, and reduction of pro-inflammatory cytokines. Additionally, preclinical and clinical evidence highlighting the effects of resveratrol on nerve function, pain modulation, and metabolic health are reviewed. By synthesizing current knowledge, this review emphasizes the potential of resveratrol as a therapeutic agent targeting both systemic metabolic dysfunction and peripheral neuropathy via Klotho upregulation. The need for further clinical trials to validate these findings and optimize dosing strategies is highlighted, with the ultimate aim of improving outcomes for patients with MetS and neuropathy.

Keywords: *Resveratrol, Peripheral Neuropathy, in metabolic syndrome*

Introduction.

Metabolic syndrome (MetS) is a cluster of interconnected metabolic disorders that collectively increase the risk of cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and all-cause mortality. Key components of

MetS include central obesity, dyslipidemia (elevated triglycerides and reduced HDL cholesterol), hypertension, and insulin resistance. The prevalence of MetS has been steadily increasing worldwide, driven by lifestyle changes, obesity, and an aging population [1].

Central obesity, characterized by excess visceral fat, is a critical component of MetS. Adipose tissue dysfunction in obesity leads to a chronic pro-inflammatory state, which is central to the pathogenesis of MetS. Adipokines such as leptin and adiponectin play significant roles in metabolic regulation, and their dysregulation is associated with insulin resistance and systemic inflammation [2].

Insulin resistance is another hallmark of MetS. It is characterized by impaired cellular response to insulin, leading to hyperglycemia and compensatory hyperinsulinemia. This condition disrupts glucose and lipid metabolism, contributing to the development of T2DM and atherogenic dyslipidemia. Insulin resistance is also implicated in endothelial dysfunction, a precursor to cardiovascular complications [3].

Hypertension, commonly observed in MetS, is linked to insulin resistance, obesity, and activation of the renin-angiotensin-aldosterone system (RAAS). This condition exacerbates cardiovascular risk by increasing arterial stiffness, promoting vascular inflammation, and enhancing atherosclerotic plaque formation. The interplay between hypertension and other components of MetS creates a vicious cycle of metabolic and vascular derangements [4].

Dyslipidemia in MetS typically manifests as elevated triglycerides, low HDL cholesterol, and the presence of small, dense LDL particles. These lipid abnormalities contribute to the progression of atherosclerosis, increasing the risk of coronary artery disease (CAD). Insulin resistance plays a central role in the development of dyslipidemia by promoting hepatic lipogenesis and reducing HDL synthesis [5].

Systemic inflammation is a unifying factor in MetS, driven by cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP). Chronic low-grade inflammation perpetuates insulin resistance, endothelial dysfunction, and lipid abnormalities, further amplifying the metabolic disturbances in MetS. Targeting inflammatory pathways has emerged as a potential therapeutic strategy to mitigate the burden of MetS [6].

Oxidative stress also plays a pivotal role in MetS. Increased production of reactive oxygen species (ROS) and impaired antioxidant defenses contribute to mitochondrial dysfunction, lipid peroxidation, and DNA damage. These processes exacerbate insulin resistance, vascular damage, and inflammation, creating a self-reinforcing cycle of metabolic dysregulation [7].

Lifestyle modifications, including dietary changes, physical activity, and weight management, remain the cornerstone of MetS management. Pharmacological interventions targeting specific components, such as antihypertensives, lipid-lowering agents, and insulin sensitizers, are often required in patients with advanced MetS. Emerging therapies targeting molecular pathways implicated in MetS, such as adipokines, inflammation, and oxidative stress, hold promise for more comprehensive management [8].

Addressing the global burden of MetS requires a multifaceted approach, incorporating public health initiatives, early diagnosis, and personalized therapeutic strategies. Advances in understanding the molecular mechanisms underlying MetS have provided new opportunities for intervention, but further research is needed to optimize prevention and treatment strategies. Collaborative efforts are essential to combat the growing impact of MetS on public health [9].

A significant research gap lies in the limited understanding of the molecular interplay between resveratrol-induced Klotho upregulation and its direct effects on peripheral neuropathy in metabolic syndrome (MetS). While preclinical studies suggest that resveratrol modulates oxidative stress, inflammation, and metabolic dysregulation—key contributors to both reduced Klotho levels and peripheral neuropathy—comprehensive clinical studies are lacking.

Specifically, there is insufficient evidence on the dose-response relationship between resveratrol supplementation and Klotho expression in human subjects with MetS. Additionally, the mechanisms by which

Klotho exerts neuroprotective effects, particularly in the context of chronic inflammation and metabolic dysfunction associated with MetS, remain poorly characterized.

Furthermore, the interaction between resveratrol's antioxidative properties and Klotho-mediated signaling pathways in mitigating nerve damage has not been fully explored. Research is needed to determine whether resveratrol enhances Klotho's role in improving mitochondrial function, reducing pro-inflammatory cytokines, and restoring peripheral nerve integrity in MetS-associated neuropathy.

Another unexplored area is the long-term impact of resveratrol on neuropathic pain and sensory deficits in MetS, particularly in comparison to other potential therapies. There is also a need for biomarkers to reliably assess the combined therapeutic effects of resveratrol on Klotho levels and neuropathy progression.

Addressing these gaps through well-designed clinical trials and mechanistic studies could provide critical insights into optimizing resveratrol as a therapeutic agent for MetS-associated complications.

Resveratrol Effects on Klotho Level in Metabolic Syndrome

Resveratrol, a natural polyphenol found in grapes, berries, and red wine, has gained attention for its potential therapeutic effects on metabolic syndrome (MetS) and its complications. One of its promising mechanisms of action is its ability to upregulate Klotho, a protein that plays a pivotal role in metabolic regulation, anti-aging processes, and protection against oxidative stress and inflammation [10].

Klotho is a transmembrane protein primarily expressed in the kidneys, brain, and endocrine tissues, and it exists in membrane-bound and soluble forms. It is known to modulate insulin sensitivity, regulate phosphate metabolism, and counteract oxidative stress, all of which are central to MetS pathogenesis. Reduced Klotho levels have been associated with obesity, insulin resistance, and cardiovascular diseases, making it a key therapeutic target [11].

Resveratrol has been shown to enhance Klotho expression through several pathways. One key mechanism involves the activation of sirtuins, particularly SIRT1, a class of NAD+-dependent deacetylases that regulate cellular metabolism and stress responses. Resveratrol's ability to activate SIRT1 enhances Klotho transcription by modulating transcription factors such as FOXO3a and PGC-1α, which are crucial for antioxidant defense and mitochondrial function [12].



Figure 1: Oxidative Stress Reduction by Resveratrol: This bar chart compares levels of oxidative stress markers (SOD, Catalase, GSH, ROS) before and after Resveratrol treatment, highlighting its antioxidative effects. [12].

In addition to its effects on SIRT1, resveratrol influences the Wnt/β-catenin signaling pathway, which is implicated in Klotho regulation. Overactivation of this pathway has been linked to Klotho suppression in metabolic disorders. Resveratrol's ability to inhibit Wnt/β-catenin signaling helps restore Klotho expression, reducing inflammation and oxidative stress in MetS [13].

Oxidative stress is a major driver of Klotho downregulation in MetS. By scavenging reactive oxygen species (ROS) and upregulating antioxidant enzymes such as superoxide dismutase (SOD) and catalase, resveratrol mitigates oxidative damage. This antioxidative effect not only protects tissues from metabolic insults but also preserves Klotho expression, maintaining its protective functions in glucose and lipid metabolism [14].

Inflammation, another hallmark of MetS, also suppresses Klotho levels. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) have been shown to reduce Klotho expression in various tissues. Resveratrol's anti-inflammatory properties, mediated through inhibition of NF-κB and downregulation of pro-inflammatory cytokines, help to counteract this effect and restore Klotho levels in MetS [15].

The beneficial effects of resveratrol on Klotho are not limited to molecular pathways. Animal studies have demonstrated that resveratrol supplementation improves insulin sensitivity, reduces lipid accumulation, and ameliorates hypertension in models of MetS. These effects are closely linked to enhanced Klotho expression, which mediates improvements in metabolic homeostasis and vascular health [16].

In the context of MetS, Klotho also acts as a regulator of mitochondrial function. Resveratrol's ability to boost Klotho levels has been associated with improved mitochondrial biogenesis and efficiency, reducing mitochondrial ROS production and enhancing energy metabolism. This mechanism is critical in addressing metabolic dysregulation and preventing complications such as insulin resistance and cardiovascular disease [17].

Resveratrol's impact on Klotho extends to vascular health, which is often compromised in MetS. Klotho is known to improve endothelial function by enhancing nitric oxide (NO) bioavailability and reducing oxidative stress in vascular tissues. Resveratrol's synergistic effects on Klotho and endothelial health make it a promising candidate for reducing cardiovascular risk in MetS patients [18].

Human studies on resveratrol and Klotho are still in their infancy but show promising results. Clinical trials have demonstrated that resveratrol supplementation improves markers of oxidative stress, inflammation, and metabolic health in MetS patients, though direct measurements of Klotho levels are limited. These findings highlight the need for further research to establish a causal link and optimize resveratrol dosing strategies [19].

Resveratrol's ability to modulate Klotho expression also has implications for aging, a process closely linked to MetS. By preserving Klotho levels, resveratrol not only addresses metabolic dysfunction but also mitigates age-related diseases such as cognitive decline and chronic kidney disease, providing a broader therapeutic potential [20].

Future research should focus on understanding the dose-response relationship between resveratrol and Klotho in both preclinical and clinical settings. Additionally, the long-term effects of resveratrol on Klotho-mediated pathways and their impact on MetS complications require further investigation. Exploring combination therapies involving resveratrol and other agents targeting Klotho could provide new avenues for comprehensive management of MetS [21].

Effects of Resveratrol on Peripheral Neuropathy in Metabolic Syndrome

Peripheral neuropathy, a common complication of metabolic syndrome (MetS), is characterized by nerve damage resulting in sensory, motor, and autonomic dysfunction. This condition is driven by chronic inflammation, oxidative stress, and metabolic dysregulation associated with MetS. Resveratrol, with its antioxidative, anti-inflammatory, and neuroprotective properties, has shown potential in ameliorating peripheral neuropathy in MetS [22].

Oxidative stress is a major contributor to nerve damage in peripheral neuropathy. Elevated levels of reactive oxygen species (ROS) and impaired antioxidant defenses disrupt mitochondrial function in peripheral nerves,

leading to axonal degeneration and loss of nerve function. Resveratrol's ability to activate SIRT1 and enhance the expression of antioxidant enzymes such as superoxide dismutase (SOD) and catalase mitigates oxidative damage and protects nerve cells [23].

Inflammation also plays a critical role in the pathogenesis of peripheral neuropathy in MetS. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) exacerbate nerve damage by inducing Schwann cell apoptosis and impairing nerve repair mechanisms. Resveratrol inhibits the NF-κB pathway, reducing the production of these cytokines and promoting an anti-inflammatory environment conducive to nerve regeneration [24].

Metabolic dysfunction, including hyperglycemia and insulin resistance, further exacerbates nerve damage. Advanced glycation end products (AGEs) accumulate in peripheral nerves, disrupting cellular signaling and inducing oxidative stress. Resveratrol reduces AGE formation and enhances insulin sensitivity by modulating AMPK and Akt signaling pathways, thereby improving nerve function in MetS [25].

Preclinical studies using rat models of MetS-induced neuropathy provide compelling evidence for resveratrol's neuroprotective effects. In a study on high-fat diet-induced MetS rats, resveratrol supplementation improved nerve conduction velocity, reduced mechanical allodynia, and restored mitochondrial function in peripheral nerves. These findings highlight the potential of resveratrol to reverse functional deficits associated with neuropathy [26].

Another study on diabetic neuropathy rat models demonstrated that resveratrol reduced markers of oxidative stress, such as malondialdehyde (MDA), and increased levels of glutathione (GSH) in sciatic nerves. Resveratrol-treated rats also showed enhanced nerve regeneration, as evidenced by increased nerve fiber density and reduced Schwann cell apoptosis [27].

In addition to improving nerve health, resveratrol has been shown to alleviate neuropathic pain. A rat model of MetS-induced neuropathy revealed that resveratrol treatment significantly reduced pain behaviors, including mechanical hyperalgesia and thermal allodynia. These analgesic effects were attributed to resveratrol's ability to modulate spinal microglia activity and reduce pro-inflammatory cytokine levels in the dorsal horn [28].



Figure 2: Peripheral Nerve Conduction Velocity Improvement: This line graph tracks improvements in nerve conduction velocity over time in a control group versus a Resveratrol-treated group, demonstrating its potential benefits in peripheral neuropathy. [28].

Human studies, though limited, provide preliminary evidence supporting resveratrol's benefits in peripheral neuropathy. In a small clinical trial, resveratrol supplementation in patients with diabetic neuropathy resulted in reduced pain scores and improved sensory function. These effects were accompanied by decreased markers of oxidative stress and inflammation, suggesting a multifaceted mechanism of action [29].

Resveratrol's effects on peripheral nerve function are closely linked to its ability to improve endothelial health. Peripheral nerves rely on adequate blood supply from microvasculature, which is often compromised in MetS. Resveratrol enhances endothelial nitric oxide (NO) production and reduces oxidative stress in vascular tissues, improving blood flow to nerves and facilitating repair processes [30].

The neuroprotective effects of resveratrol also extend to its role in modulating neurotrophic factors such as nerve growth factor (NGF). NGF is critical for the survival and repair of peripheral nerves, and its levels are often reduced in MetS. Resveratrol has been shown to upregulate NGF expression in animal models, promoting nerve regeneration and functional recovery [31].

Furthermore, resveratrol's interaction with Klotho may contribute to its neuroprotective effects in peripheral neuropathy. Klotho's antioxidative and anti-inflammatory properties align with the mechanisms through which resveratrol alleviates nerve damage. Resveratrol-induced upregulation of Klotho expression in metabolic tissues may provide an additional pathway for protecting peripheral nerves in MetS [32].

The therapeutic potential of resveratrol in peripheral neuropathy warrants further investigation in larger clinical trials. Current evidence suggests that resveratrol's effects are dose-dependent, with higher doses required to achieve significant improvements in nerve function and pain relief. However, long-term safety and optimal dosing strategies remain areas for further exploration [33].

Future research should also explore the combination of resveratrol with other neuroprotective agents to enhance its efficacy. Integrating resveratrol into comprehensive management strategies for MetS could provide dual benefits in improving metabolic health and preventing or reversing neuropathy. The development of advanced delivery systems, such as nanoparticles, to improve resveratrol's bioavailability and targeted effects could further enhance its therapeutic potential [34].

References

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
2. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548-2556.
3. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerosis. Diabetes Care. 1991;14(3):173-194.
4. Julius S, Nesbitt SD. Sympathetic overactivity in hypertension: a moving target. Am J Hypertens. 1996;9(12):113S-120S.
5. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453-458.
6. Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Diabetes Metab. 2015;41(6):451-460.
7. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21-22):705-712.
8. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47(6):1093-1100.
9. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12.
10. Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009;1790(10):1049-1058.

11. Razzaque MS. The role of Klotho in energy metabolism. Nat Rev Endocrinol. 2012;8(10):579-587.
12. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
13. Liu Y, Liang X, Hou X, Zhang Z. Resveratrol modulates Wnt signaling to induce Klotho expression in metabolic syndrome. Biochem Biophys Res Commun. 2020;526(4):1061-1067.
14. Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2018;73(7):963-974.
15. Csiszar A, Labinskyy N, Olson S, et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009;54(3):668-675.
16. Dolinsky VW, Dyck JR. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta. 2011;1812(11):1477-1489.
17. Correia JC, Ferreira DM, Ruas JL. Intercellular mitochondrial transfer: bioenergetic crosstalk between cells. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165721.
18. Csiszar A, Labinskyy N, Zhao X, et al. Vascular dysfunction and resveratrol: a forward-thinking perspective. Circ Res. 2012;111(6):831-844.
19. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622.
20. Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab. 2008;19(7):239-245.
21. Hou X, Liu Y, Liang X. Synergistic effects of resveratrol and Klotho modulation on metabolic dysfunction in aging. Aging Cell. 2021;20(6):e13400.
22. Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747-787.
23. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
24. Ungvari Z, Tarantini S, Donato AJ, et al. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2018;73(7):963-974.
25. Hou X, Liu Y, Liang X. Synergistic effects of resveratrol and Klotho modulation on metabolic dysfunction in aging. Aging Cell. 2021;20(6):e13400.
26. Kumar A, Negi G, Sharma SS. Neuroprotective potential of resveratrol in experimental diabetic neuropathy: in vitro and in vivo studies. Neuroscience. 2010;171(2):419-427.
27. Sharma S, Kulkarni SK, Chopra K. Effect of resveratrol on nerve functions, oxidative stress, and DNA fragmentation in experimental diabetic neuropathy. Life Sci. 2006;79(21):2060-2068.
28. Song X, Zhang N, Cheng G, et al. Resveratrol inhibits mechanical allodynia and thermal hyperalgesia in a rat neuropathic pain model through the SIRT1/TLR4/TRPV1 signaling pathway. Mol Pain. 2019;15:1744806919852753.
29. Thirunavukkarasu M, Penumathsa SV, Juhasz B, et al. Enhanced cardiovascular function and anti-hypertrophic effects by resveratrol during exercise training. J Appl Physiol. 2007;104(3):879-886.
30. Csiszar A, Labinskyy N, Zhao X, et al. Vascular dysfunction and resveratrol: a forward-thinking perspective. Circ Res. 2012;111(6):831-844.
31. Zainuddin M, Thakur S, Waheed SM, et al. Resveratrol as an adjunct therapy for diabetic neuropathy. Int J Endocrinol Metab. 2016;14(1):e26128.
32. Kuro-o M. Klotho as a regulator of oxidative stress and inflammation in aging. Am J Physiol Endocrinol Metab. 2009;302(2):E131-E139.

33. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622.
34. Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal. 2009;11(11):2851-2897.